Published 2 days ago • loading... • Updated 2 days ago

How innovative genomic testing is transforming early breast cancer care

Agendia initiated the FLEX Study , a large-scale observational research effort that has currently enrolled more than twenty thousand individuals diagnosed with early-stage breast cancer.
The study aims to address racial and ethnic differences by including diverse populations and follow patients for more than 10 years to inform personalized breast cancer care.
Genomic tests like MammaPrint and BluePrint provide insights that can reclassify tumor risk and identify aggressive tumor behavior beyond standard pathology.
Dr. Joyce O'Shaughnessy noted the FLEX Study’s diverse enrollment as an extraordinary achievement that supports personalized treatment decisions to improve outcomes.
The FLEX Study could transform breast cancer care by advancing scientific understanding and ensuring precision medicine benefits women of all backgrounds.

Insights by Ground AI

Does this summary seem wrong?

38 Articles

All

Left

Center

Right

The Virgin Islands Daily News

+37 Reposted by 37 other sources

Center

How innovative genomic testing is transforming early breast cancer care

(BPT) - When a woman receives a breast cancer diagnosis, the journey ahead can feel overwhelming. Breast cancer affects one in eight women in their lifetime, and while treatment options have advanced significantly in recent years, not all women have…

2 days ago·Cherokee County, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year